# Wille AG

> Wille AG is a VC fund in Zürich backing Health Care, Therapeutics and Biotechnology. See 3 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Zürich, Switzerland
- Total investments: 3
- Last investment: Oct 2022
- Lead investor: 0%
- Last updated: Aug 2026

Wille AG is a VC fund in Zürich focused on Health Care and Therapeutics. Wille AG

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 2 | 67% |
| Therapeutics | 2 | 67% |
| Biotechnology | 2 | 67% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 2 | 67% |
| Series C | 1 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 2 | 67% |
| Switzerland | 1 | 33% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Araris Biotech | Araris Biotech AG (Araris) is a biotechnology start-up company. Their aim is to deliver a breakthrough technology platform that enables the development of next-generation ADC-based safe and potent drugs for various diseases and ailments.They are committed to produce high quality ADCs that do not require any engineering (antibody and/orcell-line) for site-specific conjugation instead the antibodies can directly be taken 'off-the-shelf'. The site-specifically modified ADCs can thus be produced rapidly within a few days and quality control and analysis can be performed quickly with high confidence. Their ADC technology is backed by two patents. | $24M | Series A | Oct 04, 2022 |  |
| Visus Therapeutics | Visus Therapeutics is a clinical-stage company developing innovative medicines to improve the vision for people around the world. | $36M | Series A | Mar 09, 2021 |  |
| Raziel Health | Raziel Health’s mission is to bring world-class, disruptively less expensive healthcare to everyone, in the comfort of their home. Its unique, integrated system combines easy-to-use technologies that support positive patient experience, enable timely clinical intervention, and meet individual patient goals while using data analytics to supportwellness and disease management. | $22M | Series C | Dec 18, 2019 |  |

3 of 3 investments shown.

## Co-investors
- [Wille Finance](https://shizune.co/investors/profile/wille-finance) — VC Fund, 3 deals together
- [4BIO Capital](https://shizune.co/investors/profile/4bio-capital-partners) — VC Fund, 1 deal together
- [b2venture](https://shizune.co/investors/profile/btovpartners) — VC Fund, 1 deal together
- [Catalyst Fund LP](https://shizune.co/investors/profile/catalyst-fund-lp) — VC Fund, 1 deal together
- [Docor International Management](https://shizune.co/investors/profile/docor-international-management) — VC Fund, 1 deal together
- [Institute for Follicular Lymphoma Innovation](https://shizune.co/investors/profile/follicular-lymphoma-innovation) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Wille AG invest in?

Wille AG invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series A and Series C stage. Most of the 3 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Wille AG last invest?

The most recent investment recorded for Wille AG closed in Oct 2022. Shizune tracks 3 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co